



**Universiteit
Leiden**
The Netherlands

The post-venous thromboembolism functional status scale: from call to action to application in research, extension to COVID-19 patients, and its use in clinical practice

Jong, C.M.M. de; Boon, G.J.A.M.; , Y.N.J. le; Barco, S.; Siegerink, B.; Klok, F.A.

Citation

Jong, C. M. M. de, Boon, G. J. A. M., Barco, S., Siegerink, B., & Klok, F. A. (2023). The post-venous thromboembolism functional status scale: from call to action to application in research, extension to COVID-19 patients, and its use in clinical practice. *Seminars In Thrombosis And Hemostasis*, 49(7), 764-773. doi:10.1055/s-0043-1764467







Version: Publisher's Version

License: [Creative Commons CC BY-NC-ND 4.0 license](https://creativecommons.org/licenses/by-nc-nd/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3731495>

Note: To cite this publication please use the final published version (if applicable).

The Post-Venous Thromboembolism Functional Status Scale: From Call to Action to Application in Research, Extension to COVID-19 Patients, and Its Use in Clinical Practice

Cindy M. M. de Jong, MD¹  Gudula J.A.M. Boon, MD, PhD¹  Y. N. Jenny Le, BSc² 
Stefano Barco, MD, PhD³  Bob Siegerink, PhD²  Frederikus A. Klok, MD, PhD¹ 

¹Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands

²Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

³Department of Angiology, University Hospital Zurich, Zurich, Switzerland

Address for correspondence Frederikus A. Klok, MD, PhD, Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands (e-mail: f.a.klok@lumc.nl).

Semin Thromb Hemost 2023;49:764–773.

Abstract

A broad spectrum of long-term sequelae may be present in venous thromboembolism (VTE) survivors, affecting their quality of life and functioning. To monitor recovery and improve the prognosis of patients with persistent functional limitations, the development of a new outcome measure that could better capture the consequences of VTE was an unmet need. Starting as a call to action, the Post-VTE Functional Status (PVFS) scale was developed to meet this need. The PVFS scale is an easy-to-use clinical tool to measure and quantify functional outcomes after VTE by focusing on key aspects of daily life. As the scale was considered useful in coronavirus disease 2019 (COVID-19) patients as well, the Post-COVID-19 Functional Status (PCFS) scale was introduced early in the pandemic after slight adaptation. The scale has been well incorporated into both the VTE and COVID-19 research communities, contributing to the shift of focus toward patient-relevant functional outcomes. Psychometric properties have been evaluated, mainly for the PCFS scale but recently also for the PVFS scale, including validation studies of translations, showing adequate validity and reliability. In addition to serving as outcome measure in studies, guidelines and position papers recommend using the PVFS and PCFS scale in clinical practice. As broad use of the PVFS and PCFS scale in clinical practice is valuable to capture what matters most to patients, widespread implementation is a crucial next step. In this review, we discuss the development of the PVFS scale and introduction in VTE and COVID-19 care, the incorporation of the scale in research, and its application in clinical practice.

Keywords

- ▶ venous thromboembolism
- ▶ quality of life
- ▶ patient-reported outcome measure
- ▶ Post-VTE Functional Status scale
- ▶ Post-COVID-19 Functional Status scale

A broad spectrum of long-term sequelae including post-thrombotic syndrome (PTS) and post-pulmonary embolism (post-PE) syndrome may occur in venous thromboembolism (VTE) survivors, affecting their quality of life (QoL) and functioning in daily activities.^{1–14} Therefore, being able to measure functional status of patients who experienced VTE

is key to monitoring recovery and improving the prognosis of patients with persistent functional limitations by targeting their specific needs.

The Post-VTE Functional Status (PVFS) scale was introduced in 2019 as a new tool to quantify functional outcomes in patients with VTE, focusing on relevant aspects of daily life

article published online
March 20, 2023

Issue Theme Recent Advances in
Thrombosis and Hemostasis—Part IX;
Guest Editor: Sam Schulman, MD, PhD

© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.,
333 Seventh Avenue, 18th Floor,
New York, NY 10001, USA

DOI <https://doi.org/10.1055/s-0043-1764467>.
ISSN 0094-6176.

during follow-up after VTE.¹⁵ Integrating such an instrument in VTE care fits well with the increasing recognition of patient-centered outcome measures in clinical practice and the shift toward value-based healthcare.^{16–18} Since it is crucial to gain a better understanding of patients' perspectives and the impact of VTE, there is also the prevailing concept that clinical trials should evaluate outcomes that are most important to patients. Thus far, trials in VTE have focused most frequently (almost exclusively) on objective binary primary outcomes such as bleeding, recurrent VTE, and mortality.^{17,19} Adding patient-reported outcome measures (PROMS) capturing QoL and/or functional outcomes to the primary outcome instead of using PROMS as a secondary outcome or merely an afterthought would broaden the scope of such trials, facilitating translation of the findings of a trial to daily clinical practice.

The aim of this review is to provide an overview of the development of the PVFS scale, the introduction of the scale in VTE and evolution of the scale for application in coronavirus disease 2019 (COVID-19) care, the incorporation of the scale in research and the evaluation of psychometric properties, and transition to clinical practice.

Development of the PVFS scale

The development of the PVFS scale began as a call to action from the need for a new and objective tool to measure functional outcomes in VTE patients.¹⁵ Existing diagnostic and prognostic tools to measure long-term consequences of VTE historically focused on the presence of certain signs and symptoms, such as scales for diagnosis of PTS, rather than on the impact of the consequences of VTE in terms of functional outcomes. Validated questionnaires for assessment of QoL, dyspnea, pain, or anxiety did not specifically target functional outcomes either. The development of a new outcome measure that could better capture the full spectrum of the consequences of VTE potentially impacting daily life was an unmet need.

To meet this need, the PVFS scale was proposed in analogy with the modified Rankin scale that is used to measure functional outcomes after stroke.^{15,20} The PVFS scale was

developed for acute PE and deep vein thrombosis (DVT) aiming at an assessment of individual functional status, as additional instrument on top of the assessment of the conventional outcomes. Based on input from 18 VTE patients during patient focus group sessions and input from 53 international VTE experts via a Delphi analysis, the scale was further refined.²¹ Its final version and relevance were endorsed by both VTE patients and experts.

The PVFS scale is an ordinal scale that captures a full spectrum of functional outcomes in six scale grades, ranging from the absence of any functional limitations and symptoms (grade 0) to severe functional limitations (grade 4) and lastly, death (grade "D"; complete PVFS scale is shown in ►Table 1).²¹ The scale covers both limitations in usual activities and duties in daily life, as changes in lifestyle, and helps become aware of functional limitations in patients who experienced VTE. The scale grade "death" was added to allow the scale to be used to measure functional outcome as (primary) outcome in trials, and prevents survivor bias. Designed to be assessed at the time of discharge after a VTE diagnosis, after 3 months and optionally after 12 and/or 24 months following VTE diagnosis, multiple assessments of the scale also provide the ability to track functional status over time, and to capture changes in functional status which enables to monitor functional recovery.²² Consequently, complications after VTE can be detected early. To facilitate comparison between pre-VTE functional status and functional status after the VTE diagnosis, a PVFS scale grade referring to the functional status 1 month prior to the VTE could also be obtained. The PVFS scale can either be self-reported by the patient with the use of an extensive patient questionnaire or a concise flowchart for patient self-report or be assessed during a short, structured interview (resources in ►Appendix). The latter facilitates the assignment of patients to scale grades with reduced subjectivity, which is recommended in the setting of clinical trials. Using the self-reported questionnaire or flowchart, the patient's perspective can be captured during assessment of the consequences of VTE on functional status. An overview of the steps of development of the PVFS scale is shown in ►Table 2.

Table 1 Post-VTE Functional Status (PVFS) scale²¹

PVFS scale grade		Description
0	No functional limitations	All usual duties/activities at home or at work can be performed at the same level of intensity. Symptoms, pain, and anxiety are absent
1	Negligible functional limitations	All usual duties/activities at home or at work can be performed at the same level of intensity, despite some symptoms, pain, or anxiety
2	Slight functional limitations	Usual duties/activities at home or at work are performed at a lower level of intensity or are occasionally avoided due to symptoms, pain, or anxiety
3	Moderate functional limitations	Usual duties/activities at home or at work have been structurally modified (reduced) due to symptoms, pain, or anxiety
4	Severe functional limitations	Assistance needed in activities of daily living due to symptoms, pain, or anxiety: nursing care and attention are required
D	Death	Death occurred before assessment

Abbreviation: VTE, venous thromboembolism.

Table 2 Overview of the steps of development of the PVFS scale

Steps of development		Status of the PVFS scale	References
1	Review of evidence for functional scales and tools assessing functional status in patients with VTE	✓	15
2	Identification of the key characteristics of the modified Rankin scale for patients with stroke to draft measure and item specifications, and fields of applicability which may be relevant for patients with VTE	✓	15
3	Assemble a dedicated multidisciplinary work group (including patients, and physicians, nurses, and representatives of major societies) to achieve consensus on the instrument	✓	21
4	Formal rounds of review of the proposed categories of the ordinal scale from the dedicated multidisciplinary work group	✓	21
5	Formal assessment of reliability and validity of the scale	✓	21
6	Next research topics:	Ongoing	
	- Formal assessment of validity and reliability of the scale in clinical trials, including translated versions of the scale into other languages (<i>face validity, construct validity, concurrent validity</i>)	✓	PVFS ^{21,23} PCFS ^{32,34,37,39,43}
	- Formal evaluations of assessment methods; blinded vs. nonblinded raters, and structured interview vs. self-report	Ongoing	PVFS ²¹ PCFS ^{40,43}
	- Assessment of inter-rater agreement of structured interviews	✓	PVFS ²¹ PCFS ³⁵
	- Assessment of variability in time of the scale grades following (the intended) time points for assessing functional status (<i>predictive validity</i>)	Ongoing	PVFS ^{52,66,67} PCFS ^{46-48,51,54,55,57-60,62-64}
	- Formal assessment of feasibility, e.g., logistics and costs, of the scale in clinical trials	Planned	
	- Relating quality of life and utilities to functional status, with focus on cultural differences	Ongoing	PCFS ^{33,34,43}
	- Evaluation of context- and culture-dependent interpretation of the different categories of functioning	Planned	
	- Relating functional status to relevant long-term endpoints, including economic endpoints (healthcare utilization, income, benefits use, etc.) and utilities	Planned	
7	Dissemination and implementation in both research protocols and clinical practice for routinely collected data analyses (quality indicator)	Ongoing	PVFS ^{18,66-68,76} PCFS ^{54-65,70-75}

Abbreviations: PCFS, Post-COVID-19 Functional Status; PVFS, Post-VTE Functional Status; VTE, venous thromboembolism.

Validity of the PVFS scale

To validate the construct validity of the PVFS scale in patients with VTE, a prospective cohort study of 211 patients was recently performed.²³ Assessed at baseline and at follow-up visit 3 to 6 months after diagnosis of VTE, correlation of the PVFS scale with PROMIS short-form physical function ($\rho = -0.67$ and -0.63 at baseline and follow-up) and EuroQoL 5-dimension 5-level (EQ-5D-5L) index ($\rho = -0.61$ for both baseline and follow-up) was found to be moderate, suggesting an adequate construct validity.²³ Also, correlation between PVFS scale and disease-specific QoL questionnaires was evaluated, which was weak to moderate at baseline ($\rho = 0.32$ and -0.53 for PEmb-QoL and VEINES-QoL summary scores, respectively) and, more relevant in the setting for clinical trials, moderate to strong at follow-up ($\rho = 0.53$ and -0.71 for PEmb-QoL and VEINES-QoL summary scores). Adequate responsiveness was observed, as change over time in PVFS scale grade was significantly associated with corre-

sponding change in PROMIS short-form physical function score.²³ During the optimization of the PVFS scale, the inter-rater agreement between patient self-report and assessment via the structured interview, as well as between different raters assigning a scale grade based on the structured interview, was shown to be good to excellent ($\kappa = 0.75$, 95% confidence interval [CI]: 0.58–1.0 and $\kappa = 1.0$, 95% CI: 0.83–1.0, respectively).²¹

Application of the PVFS scale in COVID-19

Almost 3 years since the outbreak of the COVID-19 pandemic, over 655 million confirmed cases of COVID-19 have been reported globally.²⁴ Given the large number of COVID-19 survivors recovering from the infection, a great need for reproducible tools to adequately monitor the course of the disease and assess the impact of symptoms on functioning emerged early in the pandemic. Considering the high incidence of acute PE in COVID-19 and occurrence of

cardiovascular complications in COVID-19,^{25–27} we considered whether the PVFS scale was useful in COVID-19 patients as well quite early in the pandemic. Hence, we have pivoted the PVFS scale into the Post-COVID-19 Functional Status (PCFS) scale. After slight adaptation of the PVFS scale (i.e., the wording “VTE” was replaced by “COVID-19”), and consultation with relevant specialists, the PCFS scale was proposed in a letter to the editor to measure functional status after severe acute respiratory coronavirus 2 (SARS-CoV-2) infection and monitor functional recovery of COVID-19.²⁸ Fully aware of limitations of an adaptation developed for a different setting, we believed that the clinical similarities and the pressing circumstances justified this proposal as it would help identify patients with poor or worse functional outcome or incomplete recovery, which could help guiding efficient use of resources in post-COVID-19 care. The PCFS scale is intended to be assessed at the time of hospital discharge, in the first weeks after discharge to monitor direct recovery (e.g., 4 and 8 weeks postdischarge), and 6 months after COVID-19 diagnosis to evaluate the presence and degree of persistent functional disabilities, as described in the manual (resources in **Appendix**).²⁹ Further justification for the use of an ordinal outcome came from the COVID-19 blueprint of the World Health Organization (WHO), which also proposed an ordinal scale as the outcome for early acute treatment trials.³⁰

During the COVID-19 pandemic, lack of resources could have contributed to suboptimal use of the scale. Therefore, we set out to investigate the implementation and application of the PCFS scale in research projects and clinical practice by conducting interviews and a questionnaire among users of the PCFS scale known to the authors. Semistructured interviews about use of the PCFS scale were conducted with healthcare professionals and researchers, representing different settings in which the PCFS scale was applied such as clinical trials or observational studies, and clinical practice including rehabilitation setting, outpatient clinic, and hospital ward. The questionnaire was distributed among PCFS collaborators to elicit their experience with use of the scale. A full report on the findings can be found on our PCFS resource page, with its highlights further summarized below.³¹

Seven interviews were conducted by one researcher (Y.N.J. L.). The majority of the interviewees used the PCFS scale in combination with other validated instruments, and all believed that the PCFS scale is easy to use. It was mentioned that using the PCFS scale alone could be insufficient; the scale should be used in combination with other outcome measures such as scores that assess symptom burden or QoL. It was also noted that preexisting functional limitations before SARS-CoV-2 infection (e.g., mobility issues and wheelchair use) are not taken into account. Assessment of a pre-COVID-19 scale grade reflecting functional status prior to COVID-19 could be a solution to this, by allowing changes in functional status after the infection to be recorded.

After approaching 100 research groups who had been in touch with the PCFS principals for more information on the PCFS scale to participate in the survey, 65 participants responded and 54 participants completed the questionnaire

of whom 39 used the scale in research (17/39) or clinical settings (4/39), or both (18/39). Of those participants, 67% reported to be using the patient-reported questionnaire for assessment of the PCFS scale, 51% the structured interview, and 33% the flowchart for patient self-report. According to the experiences of the participants, 51% had encountered application of the scale by researchers, 41% by physicians, and 31% by patients themselves through self-report. On a scale from 0 (disagree) to 10 (agree), the participants reported a median of 8 for the statements “easy for physicians to use and understand” and “recommend the scale to other colleagues,” and a median of 10 for the statements “easy for patients to use and understand” and “useful as a tool in the SARS-CoV-2 pandemic.” These ratings confirm that the PCFS scale is useful and easy to apply and interpret.

Validity of the PCFS scale

As the entire research community shifted focus to COVID-19 during the last years, there was focus on the PCFS scale as well. We first provide an overview of the evidence obtained from PCFS studies and then extrapolate to the PVFS scale. The construct validity has been demonstrated for the first time among 1,939 adult self-selected individuals with confirmed and presumed COVID-19 at 3 months after symptom onset.³² For increasing PCFS scale grades from grade 2 upward (e.g., worsening of functional status: slight, moderate to severe functional limitations), individuals were found to have a gradual rise in number and intensity of symptoms (–**Fig. 1**) as well as in impairment in work and activities assessed using the Work Productivity and Activity Impairment questionnaire. Also, a decrease in health-related QoL based on the EQ-5D-5L index was found, with weak to strong correlation between functional status and the EQ-5D-5L QoL domains ($\rho = 0.23$ – 0.66 ; strongest correlation with the “usual activities” domain).³² In a cross-sectional study in which 133 COVID-19 patients were evaluated at hospital discharge, the PCFS scale was able to discriminate between increasing symptoms of fatigue, and decreasing health-related QoL as well as functional performance.³³ In a multivariable analysis, the length of in-hospital stay was found to be associated with worse functional status.³³ In a cohort of 121 COVID-19 survivors who were evaluated 2 to 9 months after hospitalization, the PCFS scale correlated moderately to strongly with the Short Form-36 questionnaire (SF-36; $\rho = -0.71$ and -0.43 for physical and mental scores, respectively), Hospital Anxiety and Depression Scale (HADS) ($\rho = 0.39$ and 0.62 for anxiety and depression scales), modified Medical Research Council dyspnea scale (mMRC; $\rho = 0.53$), and Borg dyspnea scale after 6-minute walk test ($\rho = 0.48$).³⁴ No correlations between PCFS scale and diffusing capacity for carbon monoxide or persistent abnormalities on chest computed tomography were found.³⁴ In 95 COVID-19 survivors who had no functional limitations (PCFS scale grade 0) 1 month before onset of COVID-19 symptoms, the inter-rater reliability of the structured interview, assessed by two authors at 6 months after discharge, was good at baseline and after 6-month follow-up ($\kappa = 0.68$, 95% CI: 0.46–0.90 and $\kappa =$




Fig. 1 Symptom intensity according to functional status expressed by Post-COVID-19 Functional Status scale. COVID-19, coronavirus disease; PCFS, Post-COVID-19 Functional Status. (From Machado et al³²; permission for reuse under open access license, <http://creativecommons.org/licenses/by/4.0/>.)

= 0.79, 95% CI: 0.65–0.93, respectively).^{35,36} The PCFS scale has also been used in a validation study of a new set of tools developed for monitoring consequences of long COVID, to examine the relation between the novel long COVID Symptom and Impact Tools (ST and IT) and functional status according to the PCFS scale.³⁷ Moderate correlation was found ($\rho = -0.39$ and -0.55 for long COVID ST and IT scores).

Over time, the PCFS scale has been translated into more than 25 languages available under an open access license (Creative Commons Attribution 4.0 International Public License; resources in **Appendix**). Some of these were the result of formal cross-cultural adaptation studies, and several validation studies of varying quality and focus have been

published as part of the translation process.^{38–44} The first study, describing the translation and cultural adaptation to Colombian Spanish performed by two bilingual translators whose native language was Spanish followed by review by eight postgraduate experts involved in COVID-19 patient-care, was published at the beginning of 2021.³⁸ In terms of construct/concurrent validity, correlation between the PCFS scale and other scales was assessed in studies evaluating the Spanish and Turkish version of the PCFS scale: correlations with EQ-5D-5L index and Global Activity Limitation Indicator were high, and moderate with HADS scores,⁴³ correlation with the mMRC dyspnea scale was moderate and ranged from $\rho = 0.28$ to 0.43 for subscores of the London Chest

Activities of Daily Living scale,³⁹ and correlation with the Barthel Index for Activities of Daily Living was low.^{39,43} In the cross-sectional validation study of the Spanish translation, test-retest reliability was substantial ($\kappa = 0.63$, 95% CI: 0.52–0.74). Also, the questions in the Mexican Spanish version of the scale were found to measure the same aspects of functional status, with the structured interview coming out as best (Cronbach's $\alpha = 0.84$ and 0.67 for structured interview and self-reported questionnaire, respectively),⁴⁰ and reliability of the Chilean Spanish version was demonstrated in a cross-cultural adaptation and validation study.^{41,42} In India, an ongoing study is evaluating the validation of the PCFS scale translated and adapted to Kannada language.⁴⁴

The results of the validation studies suggest that the scale captures a patient's well-being and physical state. Strongest correlations were found with the EQ-5D-5L "usual activities" domain and SF-36 physical score, confirming that the scale can be used to measure functional status. While face validity, construct validity, and concurrent validity indeed have been studied, predictive validity (i.e., the usefulness of the scale in clinical prediction relevant to the patient or medical professional) has so far been understudied. This type of studies require a longer follow-up, as well as data from other sources (such as administrative data and data on healthcare utilization), which are currently slowly becoming available for the PCFS scale.

Lessons from the PCFS scale for the PVFS scale

The COVID-19 research community responded positively to the PCFS scale and the scale was taken up well. Although predictive validity has so far been understudied, multiple studies exploring the scale's usefulness and evaluating different types of validity showed that the PCFS scale appears to measure what it aims to measure and that the scale corresponds reasonably to other relevant outcomes, especially when assessed through a structured interview. We must acknowledge that these studies have been conducted under tremendous time pressure and with limited resources. Future studies should focus on using solid methodologies and should go beyond cross-sectional designs. When designing new studies, some methodological aspects related to the use of the scale could be better taken into account, such as making sure that assessment of the scale is performed at one specific moment during follow-up with a tight time window, and inclusion of the sixth scale grade ("death") to not only focus on survivors and thus prevent selection bias. Furthermore, the timing of assessment of the PCFS scale in the first weeks postdischarge (e.g., after 4 weeks as mentioned in the manual) may be too early after discharge. As widespread use of the PVFS scale in VTE clinical practice and studies is still ahead of us, these lessons can be learned from use of the PCFS scale, which has all in all proven to be useful in studying COVID-19.

Based on this, there is enough supporting evidence for the PCFS and by extension the PVFS scale to be integrated as

additional outcome measures in clinical practice and research settings. Indeed, multiple studies have included the PCFS or PVFS scale as an outcome measure. The PCFS scale is being used in diverse COVID-19 and VTE research projects, including (ongoing) clinical trials and observational studies across the world, such as the OVID randomized trial studying primary thromboprophylaxis in high-risk outpatients with COVID-19.^{45–65} For post-PE care specifically, the PVFS scale is included in the study protocols of the large Pulmonary Embolism International Thrombolysis (PEITHO)-3, Higher-Risk Pulmonary Embolism Thrombolysis (HI-PEITHO), and SAFE-SSPE (Surveillance versus Anticoagulation For low-risk patiEnts with isolated SubSegmental Pulmonary Embolism) randomized controlled trials, to measure functional status at different time points during the follow-up period as one of the secondary outcomes.^{66–68} Future VTE trials may sometime evaluate functional outcome as (co)primary outcome, following the example of the modified Rankin scale, which is the most prevalent functional outcome measure used in stroke research.⁶⁹

Clinical Application

Not only have the PVFS and PCFS scales been applied in studies to evaluate psychometric properties or to serve as outcome measures, the scales are also recommended in guidelines and position papers to be used in clinical practice. The PCFS scale is recommended in the Chilean national interdisciplinary consensus guidance on revalidation after COVID-19, the German guideline on diagnostics and treatment strategies in long COVID, and a clinical guidance document for follow-up and care of patients with persistent symptoms after COVID-19 published by the Catalan Health Service.^{70–73} Also, a consensus statement on post-COVID-19 physiotherapy for the Indian context recommends the PCFS scale as an outcome measure to monitor progress in post-COVID-19 rehabilitation.⁷⁴ In addition, the WHO guideline on clinical management of COVID-19 patients was published in September 2022, which includes the PCFS scale.⁷⁵ The scale is described in the section on referral of adults with post-COVID-19 condition for rehabilitation as a validated instrument to assess functional status, endorsing the usefulness of the scale in practice. Lastly, the position paper of the European Society of Cardiology on optimal follow-up after acute PE, endorsed by the European Respiratory Society, includes the recommendation to assess the presence of functional limitations and chronic symptoms in a standardized manner with the use of validated tools, mentioning the PVFS scale as such a tool.⁷⁶

Recently, a standardized set of outcome measures for patients with VTE has been developed, with outcomes and outcome measures selected by international patient representatives and VTE experts through a modified Delphi process.¹⁸ This consensus recommendation includes the outcomes that are deemed most important to patients with VTE to measure during follow-up after the VTE diagnosis. One of the core outcomes considered important is functional limitations, which is recommended to be

measured by the PVFS scale.¹⁸ Integration of patient-reported outcome measures such as the PVFS scale in clinical practice is believed to improve care for VTE patients and to contribute to the delivery of value-based healthcare. Furthermore, routine use of such measures will empower patients to be actively engaged in the management of their disease. With the development of this standardized set, the first steps toward patient-centered care have been taken, leading to implementation being the next important step. As the scale is a brief tool that is easy to use and interpret, it is considered to offer great potential when it comes to implementation of patient-reported instruments in daily practice.⁷⁷

The PCFS scale was included as a potential outcome measurement instrument in a similar Delphi process (Post-COVID-19 Condition Core Outcome Set [PC-COS] study, available via PC-COS.org), as it was thought to measure relevant outcome domain(s) part of the core outcome set developed for post-COVID-19 condition.⁷⁸ However, no consensus was reached, for multiple domains, as to which tool was best to assess these domains. The PCFS scale was ultimately not included as one of the recommended instruments to assess multiple domains, as preference was given to more established tools such as the SF-36, EQ-5D, and WHO Disability Assessment Schedule 2.0. Novel COVID-19-specific tools that were noted are the COVID-19 Yorkshire Rehabilitation Screening scale and the Symptom Burden Questionnaire for Long COVID. Despite their names, both instruments are scores only, thus leaving out some of the methodological advantages of using an ordinal outcome. A reason why the PCFS scale was not included might be that these instruments were developed from scratch, while the PCFS scale is based on the PVFS scale which affected the formal evaluation within the Delphi/COSMIN (Consensus-based Standards for the selection of health Measurement INstruments) process. Ultimately, the PC-COS study group describes that “At the online consensus meeting, there was a very high level of support for future research focused on a consensus process regarding use of existing outcome measurement instruments versus long COVID-specific instruments, versus a combination of both types of instruments for post-COVID-19 condition/long COVID research and clinical practice,” a statement adequately describing the path toward more evidence and experience to measure the long-term effects of COVID-19.

Conclusion

Starting as a call to action, the PVFS scale was developed to meet the need for a tool to measure and quantify functional outcomes after VTE, to capture the impact of persistent symptoms on functioning. Early in the COVID-19 pandemic, the scale was considered to be useful in COVID-19 patients as well, leading to the introduction of the PCFS scale. The PVFS and PCFS scale have been well incorporated into both the VTE and COVID-19 research communities. Psychometric properties have been evaluated in several studies, mainly for the PCFS scale but recently also for the PVFS scale, showing adequate face validity, construct validity, concurrent validity, and reli-

ability. Clinical studies, both completed and ongoing, have included the PVFS and PCFS scale as an outcome measure, which contributes to focus on patient-relevant functional outcome in addition to conventional outcomes. Consistent with the increased appreciation of patient-centered outcome measures, broad use and implementation of the PVFS and PCFS scale in clinical practice is valuable to capture what matters most to patients.

Conflict of Interest

F.A.K. reports grants or contracts from Bayer, BMS, BSCI, MSD, Leo Pharma, Actelion, Pharm-X, the Netherlands Organization for Health Research and Development, the Dutch Thrombosis Association, the Dutch Heart Foundation, and the Horizon Europe Program, all unrelated to this work and paid to his institution.

C.M.M.d.J., G.J.A.M.B., Y.N.J.L., S.B., and B.S. report no conflicts of interest related to this work.

References

- 1 Kahn SR, Ducruet T, Lamping DL, et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. *Arch Intern Med* 2005;165(10):1173–1178
- 2 Kahn SR, Comerota AJ, Cushman M, et al; American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. *Circulation* 2014;130(18):1636–1661
- 3 Klok FA, van Kralingen KW, van Dijk AP, et al. Quality of life in long-term survivors of acute pulmonary embolism. *Chest* 2010;138(06):1432–1440
- 4 Sista AK, Klok FA. Late outcomes of pulmonary embolism: the post-PE syndrome. *Thromb Res* 2018;164:157–162
- 5 Sista AK, Miller LE, Kahn SR, Kline JA. Persistent right ventricular dysfunction, functional capacity limitation, exercise intolerance, and quality of life impairment following pulmonary embolism: systematic review with meta-analysis. *Vasc Med* 2017;22(01):37–43
- 6 Kahn SR, Akaberi A, Granton JT, et al. Quality of life, dyspnea, and functional exercise capacity following a first episode of pulmonary embolism: results of the ELOPE Cohort Study. *Am J Med* 2017;130(08):990.e9–990.e21
- 7 Valerio L, Barco S, Jankowski M, et al. Quality of life 3 and 12 months following acute pulmonary embolism: analysis from a prospective multicenter cohort study. *Chest* 2021;159(06):2428–2438
- 8 Giustozzi M, Valerio L, Agnelli G, et al. Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. *Eur J Intern Med* 2021;88:43–51
- 9 Klok FA, van der Hulle T, den Exter PL, Lankeit M, Huisman MV, Konstantinides S. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. *Blood Rev* 2014;28(06):221–226
- 10 Valerio L, Mavromanoli AC, Barco S, et al; FOCUS Investigators. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. *Eur Heart J* 2022;43(36):3387–3398
- 11 Boon GJAM, Huisman MV, Klok FA. Determinants and management of the post-pulmonary embolism syndrome. *Semin Respir Crit Care Med* 2021;42(02):299–307

- 12 Klok FA, Mos IC, Broek L, et al. Risk of arterial cardiovascular events in patients after pulmonary embolism. *Blood* 2009;114(08):1484–1488
- 13 Klok FA, Zondag W, van Kralingen KW, et al. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. *Am J Respir Crit Care Med* 2010;181(05):501–506
- 14 Huisman MV, Barco S, Cannegieter SC, et al. Pulmonary embolism. *Nat Rev Dis Primers* 2018;4:18028
- 15 Klok FA, Barco S, Siegerink B. Measuring functional limitations after venous thromboembolism: a call to action. *Thromb Res* 2019;178:59–62
- 16 Porter ME. What is value in health care? *N Engl J Med* 2010;363(26):2477–2481
- 17 Genge L, Krala A, Tritschler T, et al. Evaluation of patients' experience and related qualitative outcomes in venous thromboembolism: a scoping review. *J Thromb Haemost* 2022;20(10):2323–2341
- 18 Gwozdz AM, de Jong CMM, Fialho LS, et al. Development of an international standard set of outcome measures for patients with venous thromboembolism: an International Consortium for Health Outcomes Measurement consensus recommendation. *Lancet Haematol* 2022;9(09):e698–e706
- 19 Tritschler T, Cusano E, Langlois N, et al. Identification of outcomes in clinical studies of interventions for venous thromboembolism in non-pregnant adults: a scoping review. *J Thromb Haemost* 2022;20(10):2313–2322
- 20 van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. *Stroke* 1988;19(05):604–607
- 21 Boon GJAM, Barco S, Bertoletti L, et al. Measuring functional limitations after venous thromboembolism: optimization of the Post-VTE Functional Status (PVFS) Scale. *Thromb Res* 2020;190:45–51
- 22 Post-VTE Functional Status Scale Manual. Manual to the Post-VTE Functional Status Scale for physicians and study personnel – including corresponding structured interview and assessment tools. Published December 2019. Accessed 23 November 2022 at: <https://www.thrombosisresearch.com/cms/10.1016/j.thromres.2020.03.020/attachment/89ffc37f-73b5-4afb-941b-121403f351b4/mmc3.pdf>
- 23 Steiner D, Nopp S, Weber B, et al. The post-VTE functional status scale for assessment of functional limitations in patients with venous thromboembolism: construct validity and responsiveness in a prospective cohort study. *Thromb Res* 2023;221:1–6
- 24 World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2023. Accessed January 03, 2023 at: <https://covid19.who.int/>
- 25 Task Force for the management of COVID-19 of the European Society of Cardiology. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. *Eur Heart J* 2022;43(11):1033–1058
- 26 Task Force for the management of COVID-19 of the European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. *Eur Heart J* 2022;43(11):1059–1103
- 27 Overton PM, Toshner M, Mulligan C, et al;PVRI Innovative Drug Development Initiative. Pulmonary thromboembolic events in COVID-19-A systematic literature review. *Pulm Circ* 2022;12(03):e12113
- 28 Klok FA, Boon GJAM, Barco S, et al. The post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. *Eur Respir J* 2020;56(01):2001494
- 29 Post-COVID-19 Functional Status Scale Manual. Published July 2020. Accessed 23 November 2022 at: <https://osf.io/mpfvv>
- 30 WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis* 2020;20(08):e192–e197
- 31 Siegerink B, Boon GJAM, Barco S, Klok FA, Le YNJ. Open Science Framework (OSF). The Post-COVID-19 Functional Status (PCFS) Scale: a tool to measure functional status over time after COVID-19. Accessed January 01, 2023 at: <https://osf.io/qgpdv/>
- 32 Machado FVC, Meys R, Delbressine JM, et al. Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19. *Health Qual Life Outcomes* 2021;19(01):40
- 33 Leite LC, Carvalho L, Queiroz DM, et al. Can the post-COVID-19 functional status scale discriminate between patients with different levels of fatigue, quality of life and functional performance? *Pulmonology* 2022;28(03):220–223
- 34 Benkalfate N, Eschapaspe E, Georges T, et al. Evaluation of the Post-COVID-19 Functional Status (PCFS) Scale in a cohort of patients recovering from hypoxemic SARS-CoV-2 pneumonia. *BMJ Open Respir Res* 2022;9(01):e001136
- 35 Du HW, Fang SF, Wu SR, et al; Fujian Medical Team Support Wuhan for COVID-19. Six-month follow-up of functional status in discharged patients with coronavirus disease 2019. *BMC Infect Dis* 2021;21(01):1271
- 36 Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. *Psychol Bull* 1968;70(04):213–220
- 37 Tran VT, Riveros C, Cleprier B, et al. Development and validation of the long coronavirus disease (COVID) symptom and impact tools: a set of patient-reported instruments constructed from patients' lived experience. *Clin Infect Dis* 2022;74(02):278–287
- 38 Betancourt-Peña J, Ávila-Valencia JC, Palacios-Gómez M, Rodríguez-Castro J, Benavides-Córdoba V. Traducción y adaptación cultural de la escala The Post-COVID-19 Functional Status (PCFS) Scale al español (Colombia). *Rev Cuba Investig Bioméd* 2021;40(05):1–4
- 39 Çalık Kütükcü E, Çakmak A, Kınacı E, et al. Reliability and validity of the Turkish version of Post-COVID-19 Functional Status Scale. *Turk J Med Sci* 2021;51(05):2304–2310
- 40 Moreno-Torres LA, Ventura-Alfaro CE. Validation of the Post-COVID-19 Functional Status Scale into Mexican-Spanish. *J Rehabil Med Clin Commun* 2021;4:1000070
- 41 Lorca LA, Torres-Castro R, Ribeiro IL, et al. Linguistic validation and cross-cultural adaptation of the post-COVID-19 Functional Status Scale for the Chilean population. *Am J Phys Med Rehabil* 2021;100(04):313–320
- 42 Lorca LA, Leão Ribeiro I, Torres-Castro R, Sacomori C, Rivera C. Psychometric properties of the Post-COVID 19 Functional Status scale for adult COVID 19 survivors. [in Spanish]. *Rehabilitacion (Madr)* 2022;56(04):337–343
- 43 Sacristán-Galisteo C, Del Corral T, Ríos-León M, Martín-Casas P, Plaza-Manzano G, López-de-Uralde-Villanueva I. Construct validity of the Spanish version of the Post-COVID-19 Functional Status scale and validation of the web-based form in COVID-19 survivors. *PLoS One* 2022;17(06):e0269274
- 44 Clinical Trials Registry - India (CTRI). COVID 19 Functional Status Scale (PCFS): Translation, Adaptation and Validation to Kannada Language. Identifier CTRI/2021/02/031011. Accessed November 30, 2022 at: <http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=52142&EncHid=&userName=CTRI/2021/02/031011>
- 45 Foged F, Rasmussen IE, Bjørn Budde J, et al. Fidelity, tolerability and safety of acute high-intensity interval training after hospitalisation for COVID-19: a randomised cross-over trial. *BMJ Open Sport Exerc Med* 2021;7(03):e001156
- 46 Hess CN, Capell WH, Bristow MR, et al. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. *Am Heart J* 2022;246:136–143
- 47 Taboada M, Moreno E, Cariñena A, et al. Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients. *Br J Anaesth* 2021;126(03):e110–e113

- 48 Betschart M, Rezek S, Unger I, et al. One year follow-up of physical performance and quality of life in patients surviving COVID-19: a prospective cohort study. *Swiss Med Wkly* 2021;151:w30072
- 49 Mohamed Hussein AA, Saad M, Zayan HE, et al. Post-COVID-19 functional status: relation to age, smoking, hospitalization, and previous comorbidities. *Ann Thorac Med* 2021;16(03):260–265
- 50 Pant P, Joshi A, Basnet B, et al. Prevalence of functional limitation in COVID-19 recovered patients using the post COVID-19 Functional Status Scale. *JNMA J Nepal Med Assoc* 2021;59(233):7–11
- 51 Inspiration Investigators. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes. *Eur J Intern Med* 2022;103:76–83
- 52 Boon GJAM, Janssen SMJ, Barco S, et al. Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in post-PE syndrome. *Thromb Res* 2021;206:66–75
- 53 Barco S, Voci D, Held U, et al; OVID Investigators. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet Haematol* 2022;9(08):e585–e593
- 54 ClinicalTrials.gov. Vagal Nerve Stimulation for Post COVID Fatigue. Identifier: NCT05445427. Accessed January 03, 2023 at: <https://clinicaltrials.gov/ct2/show/NCT05445427?outc=%22post+covid+functional+status%22&draw=2&rank=1>
- 55 ClinicalTrials.gov. Rehabilitation for Post-COVID-19 Syndrome through a Supervised Exercise Intervention (RECOVE). Identifier: NCT04718506. Accessed January 03, 2023 at: <https://clinicaltrials.gov/ct2/show/NCT04718506?outc=%22post+covid+functional+status%22&draw=2&rank=2>
- 56 ClinicalTrials.gov. Effects of Diagrammatic Breathing with and without Resistance in Post COVID Patients on ADLs. Identifier: NCT05543551. Accessed January 03, 2023 at: <https://clinicaltrials.gov/ct2/show/NCT05543551?outc=%22post+covid+functional+status%22&draw=2&rank=3>
- 57 ClinicalTrials.gov. The Effect of Micellized Food Supplements on Health-related Quality of Life in Patients with Post-acute COVID-19 Syndrome. Identifier: NCT05150782. Accessed January 03, 2023 at: <https://clinicaltrials.gov/ct2/show/NCT05150782?outc=%22post+covid+functional+status%22&draw=2&rank=4>
- 58 ClinicalTrials.gov. Magnesium and Vitamin D Combination for Post-COVID Syndrome. Identifier: NCT05630339. Accessed January 03, 2023 at: <https://clinicaltrials.gov/ct2/show/NCT05630339?outc=%22post+covid+functional+status%22&draw=2&rank=5>
- 59 ClinicalTrials.gov. Circuit Training Program in Post COVID-19 Patients. Identifier: NCT05323331. Accessed January 03, 2023 at: <https://clinicaltrials.gov/ct2/show/NCT05323331?outc=%22post+covid+functional+status%22&draw=2&rank=6>
- 60 ClinicalTrials.gov. Efficacy of an Asynchronous Telerehabilitation Programme in Post-COVID-19 Patient. Identifier: NCT04794036. Accessed January 03, 2023 at: <https://clinicaltrials.gov/ct2/show/NCT04794036?outc=%22post+covid+functional+status%22&draw=2&rank=7>
- 61 ClinicalTrials.gov. Portable Oxygen Concentrator (POC) Versus Standard of Care in Long-COVID: Randomized Crossover Exploratory Pilot Study (RESTORE). Identifier: NCT05212831. Accessed January 03, 2023 at: <https://clinicaltrials.gov/ct2/show/NCT05212831?outc=%22post+covid+functional+status%22&draw=2&rank=8>
- 62 ClinicalTrials.gov. Prognostic of Dysfunctional Breathing in Long COVID: a Follow up Study. Identifier: NCT05217875. Accessed January 03, 2023 at: <https://clinicaltrials.gov/ct2/show/NCT05217875?outc=%22post+covid+functional+status%22&draw=2&rank=9>
- 63 ClinicalTrials.gov. Symptom-Based Rehabilitation Compared to Usual Care in Post-COVID - A Randomized Controlled Trial (RELOAD). Identifier: NCT05172206. Accessed January 03, 2023 at: <https://clinicaltrials.gov/ct2/show/NCT05172206?outc=%22post+covid+functional+status%22&draw=2&rank=10>
- 64 ClinicalTrials.gov. Long-term Effects of COVID-19. Identifier: NCT05220514. Accessed January 03, 2023 at: <https://clinicaltrials.gov/ct2/show/NCT05220514?outc=%22post+covid+functional+status%22&draw=2&rank=11>
- 65 ClinicalTrials.gov. Long-Term Respiratory Muscle Strength in Young COVID-19 Patients. Identifier: NCT05381714. Accessed January 03, 2023 at: <https://clinicaltrials.gov/ct2/show/NCT05381714?outc=%22post+covid+functional+status%22&draw=2&rank=12>
- 66 Sanchez O, Charles-Nelson A, Ageno W, et al; PEITHO-3 Investigators. Reduced-dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism: rationale and design of the Pulmonary Embolism International Thrombolysis (PEITHO)-3 trial. *Thromb Haemost* 2022;122(05):857–866
- 67 Klok FA, Piazza G, Sharp ASP, et al. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: rationale and design of the HI-PEITHO study. *Am Heart J* 2022;251:43–53
- 68 Baumgartner C, Klok FA, Carrier M, et al. Clinical Surveillance vs. Anticoagulation For low-risk patients with isolated Subsegmental Pulmonary Embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE). *BMJ Open* 2020;10(11):e040151
- 69 Quinn TJ, Dawson J, Walters MR, Lees KR. Functional outcome measures in contemporary stroke trials. *Int J Stroke* 2009;4(03):200–205
- 70 Sociedades Científicas y Colegios Profesionales del área de rehabilitación. Consenso Interdisciplinario de Rehabilitación para Personas Adultas Post COVID-19. Recomendaciones para la práctica clínica. Published August 2020. Accessed 01 December 2022 at: https://sochimfy.cl/site/docs/Consenso_20_de%20Agosto.pdf
- 71 Rabaday S, Altenberger J, Brose M, et al. Guideline S1: long COVID: diagnostics and treatment strategies [in German]. *Wien Klin Wochenschr* 2021;133(Suppl (Suppl 7)):237–278
- 72 Koczulla AR, Ankermann T, Behrends U, et al. S1 Guideline post-COVID/long-COVID. [in German]. *Pneumologie* 2021;75(11):869–900
- 73 Servei Català de la Salut. Guia clínica per a l'atenció de les persones amb símptomes persistents de COVID-19. Published March 2021. Accessed 01 December 2022 at: https://canalsalut.gencat.cat/web/.content/_A-Z/C/coronavirus-2019-ncov/professionals/materials-atencio-als-pacients-post-covid-19/guia-clinica-atencio-persones-simptomes-persistents-covid-19.pdf
- 74 Swaminathan N, Jiandani M, Surendran PJ, et al. Beyond COVID-19: evidence-based consensus statement on the role of physiotherapy in pulmonary rehabilitation in the Indian context. *J Assoc Physicians India* 2020;68(12):82–89
- 75 World Health Organization. Clinical management of COVID-19: living guideline, 15 September 2022. Geneva. (WHO/2019-nCoV/Clinical/2022.2). License: CC BY-NC-SA 3.0 IGO. 2022
- 76 Klok FA, Ageno W, Ay C, et al. Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. *Eur Heart J* 2022;43(03):183–189
- 77 Tavoly M, Asady E, Wik HS, Ghanima W. Measuring quality of life after venous thromboembolism: Who, when, and how? *Semin Thromb Hemost* 2022. Epub ahead of print
- 78 Munblit D, Nicholson T, Akrami A, et al; PC-COS Project Steering Committee. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. *Lancet Respir Med* 2022;10(07):715–724

Appendix: List of Resources

Post-VTE Functional Status (PVFS) scale: Appendix C “Manual to the post-VTE functional status scale for the structured interview as well as for the patient self-report—version December 2019.” Available via: Boon GJAM et al. Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) scale. (*Thromb Res* 2020;190:45–51. doi: 10.1016/j.thromres.2020.03.020. Epub 2020 Mar 30. PMID: 32298840.)

Post-COVID Functional Status (PCFS) scale: The structured interview and materials intended to facilitate the self-reported assessment can be found in the published manual, which is free of charge available on the PCFS resource page on OSF, accessible via <https://osf.io/qgpdv/>. Translations of the PCFS scale manual can be found on the PCFS resource page as well.